From #C3G, the Canadian Centre for Computational Genomics | Inside #GenPipes : Exploring C3G's Software Solution for Life Science Research | #CoreFacility #OpenScience #Genomics #Bioinformatics #Education 🧬 🖥️ 🧪
⬇️
computationalgenomics.ca/inside-genpi...
Sobi's Aspaveli® Secures European Commission Approval for C3G Treatment #Sweden #Stockholm #Sobi #Aspaveli #C3G
The phase 3 APPEAR-C3G study showed iptacopan significantly reduced proteinuria at 6 months in people with C3 glomerulopathy. #nephrology #nephsky #C3G
www.docwirenews.com/post/iptacop...
Early diagnosis matters in C3 glomerulopathy. This #CME activity explores symptom recognition, complement pathways, and emerging therapies.
👉 Watch now: bit.ly/48TbwXO
#MedicalEducation #Nephrology #KidneyDisease #RareDisease #C3G #GlomerularDisease
Sobi's Aspaveli® Advances Towards Approval for Rare Kidney Diseases in Europe #Sweden #Stockholm #Aspaveli #C3G #IC-MPGN
Proud of Manchester’s paediatric participation in this game-changing trial published this week in @nejm.org
A golden dawn in renal rare disease
#C3G #IC-MPGN #pegcetacoplan #complement
www.nejm.org/doi/full/10....
Dr. Carla Nester discussed 52-week data on pegcetacoplan for #C3G demonstrating sustained proteinuria reduction (and remission in a third of patients). #nephrology #nephsky #glomerulardisease #kidneywk www.docwirenews.com/post/52-week...
Very pleased to see this RCT of Pegcetacoplan in #C3G and primary #ICMPGN published because it shows evidence of a transformational effect of this treatment in people with a #RareDisease. www.nejm.org/doi/full/10....
Positive Outcomes from VALIANT Phase 3 Study Published in NEJM Highlight Pegcetacoplan's Efficacy for Kidney Diseases #Sweden #Stockholm #C3G #pegcetacoplan #IC-MPGN
#Delphi Consensus on Surrogate Endpoints in #C3G and Primary #ICMPGN
#VisualAbstract by Jade Teakell, MD
www.kireports.org/article/S2468-0249(25)00...
Join us today for two exciting sessions: our symposium ‘Decoding complement in C3G and primary IC-MPGN’ (🕙13.05 EEST,📍MC3), and Dr Licht’s oral presentation on adolescents with #C3G and primary #IC-MPGN.
Proud to contribute to the scientific dialogue that supports patient care🤝
#Nephrology
It was a pleasure attending today’s sessions and hearing insightful discussions on #C3G and #IC-MPGN💡
Tomorrow, join us for our lunchtime symposium ‘Decoding complement in C3G and primary IC-MPGN’, followed by an oral presentation focused on adolescents with these rare diseases.
#Sobi_nephrology
Ready for an exciting day at #ESPN2025. Today Dr Van de Kar will share the first of our two oral presentations on adolescent #C3G and primary #ICMPGN—part of our commitment to advancing understanding of rare #kidney_disease. #Rare_Sobi #Sobi_nephrology
🗓️Thursday 16 October
🕙17.22 EEST
📍TriantiHall
Today on C3G Awareness Day, we spotlight our SEISMIC initiative where ISGD, NephCure, and CompCure convened leading experts at the SEISMIC summit to advance C3G diagnosis and treatment. Watch the highlights:
youtu.be/GJvgbtMT3xA
youtu.be/Un02dFXyn-w
#C3GAwarenessDay #C3G #ISGD #NephCure #CompCure
On this #C3GAwarenessDay, check out:
📺 Hot Topics in GN Online Symposium with the Indian Society of Nephrology: www.youtube.com/live/E0PnEj8...
🔊 Latest GN in 10 Podcast w/Carla Nester, focusing on C3G and complement-mediated diseases: www.is-gd.org/podcast
#C3G #GlomerularDisease #ISGD
Dark Teal background with white circle in middle with yellow border. In the circle it says C3G Awareness Day. Under the circle there is a hashtag #C3GAwarenessDay, and the text Every rare kidney disease deserves to be seen.
Today is #C3GAwarenessDay! At ISGD, we stand with people living with this rare kidney disease. As a medical society for #GlomerularDisease experts, we're committed to raising awareness and moving the science forward to bring more hope and solutions to the C3G community. #C3G #ISGD
Don’t miss: 'C3G & Immune Complex MPGN Updates: Where We Are & Where We Are Headed’ -Oct 3, 25, all virtual program- latest strategies and therapeutic options. 5.0 ACCME Credits.
www.eventleaf.com/e/C3G2025
#C3G #NephPearls #RareDisease #Nephrology
In the final segment of our roundtable, the panelists share their excitement about recent developments in #nephrology and their visions for the future of #glomerulonephritis therapies. #nephsky #c3g #icmpgn www.docwirenews.com/post/an-exci...
In the fourth part of our roundtable, the panel delves into the logistics of implementing the new treatments for C3G and IC-MPGN, including safety, vaccination, and adherence. #nephsky #nephrology #c3g #icmpgn www.docwirenews.com/post/practic...
In the third part of our recent roundtable, the panel discusses the role of kidney biopsies in the clinical trials of the recently approved treatments for C3G, iptacopan and pegcetacoplan. #nephsky #nephrology #c3g #kidneybiopsy www.docwirenews.com/post/kidney-...
In part 2 of our inaugural roundtable, the panel discusses two recently approved treatments, iptacopan for C3G and pegcetacoplan for C3G and IC-MPGN. #nephrology #nephsky #c3g #icmpgn #glomerulonephritis www.docwirenews.com/post/new-the...
Inside:
- KDIGO & ERA sign new MoU
- #APOL1 Conference Report in @kidneyint.bsky.social
- Take the KDIGO Guideline Survey: kdigo.co/Global-Guide...
- KDIGO at SLANH & ANZSN
- New patient resources incl. a #C3G #ICMPGN program with @medliveofficial.bsky.social , @nordrare.bsky.social & NephCure
Wow! Second approved drug for an ultrarare disease in a few months, and with broader indication. What a milestone!
Time for EMA’s approval now.
#raredisease #glomerulardisease #c3g #nephSky
⚠️ The FDA has approved pegcetacoplan (Empaveli) for treating C3G and IC-MPGN. #kidneydisease #nephrology #nephsky #c3g www.docwirenews.com/post/fda-app...
Living with a #rarekidneydisease often means navigating a maze of late diagnoses, scarce treatment options, and daily symptom management. When #dialysis enters the picture, it can feel like one more heavy layer on an already complex journey.
More at www.rare360.life/post/managin...
#c3g #MPGN
🌋The SEISMIC meeting has ignited at our kickoff dinner. Tomorrow we will begin discussions on important issues in the shifting C3G and IC-MPGN landscape.
#GlomerularDisease #C3G #ICMPGN #SEISMIC
Pegcetacoplan reduced proteinuria and stabilized eGFR in adolescent patients with C3G or primary IC-MPGN. #kidneydisease #c3g #icmpgn #pediatrics #nephrology #nephsky #pegcetacoplan www.docwirenews.com/post/pegceta...
An analysis confirmed the efficacy and safety of #pegcetacoplan for patients with C3G/IC-MPGN and nephrotic range #proteinuria. #C3G #ICMPGN #kidneydisease #nephrology #nephsky www.docwirenews.com/post/pegceta...
📣Excited to share with the #nephrology community the latest updates in #C3G and primary #ICMPGN clinical trials at #ERA25. If you are a healthcare professional, do not miss the late breaking session: Innovative Kidney Trials at ⏲️15:00 at the Square #nephrology #kidneydisease
